Suppr超能文献

用干细胞移植治疗帕金森病的非运动症状。

Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells.

作者信息

Pantcheva Paolina, Reyes Stephanny, Hoover Jaclyn, Kaelber Sussannah, Borlongan Cesar V

机构信息

a Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, Tampa, FL, USA.

出版信息

Expert Rev Neurother. 2015 Oct;15(10):1231-40. doi: 10.1586/14737175.2015.1091727. Epub 2015 Sep 22.

Abstract

Parkinson's disease (PD) treatment-based research has focused on developing therapies for the management of motor symptoms. Non-motor symptoms do not respond to treatments targeting motor deficits, thus necessitating an urgent need to develop new modalities that cater to both motor and non-motor deficits. Stem cell transplantation is potentially therapeutic for PD, but the disease non-motor symptoms have been primarily neglected in such cell therapy regimens. Many types of stem cells are currently available for transplantation therapy, including adult tissue (e.g., bone marrow, placenta)-derived mesenchymal stem cells. The fact that mesenchymal stem cells can replace and rescue degenerated dopaminergic and non-dopaminergic cells suggests their potential for the treatment of motor as well as non-motor symptoms of PD, which is discussed in this article.

摘要

基于帕金森病(PD)治疗的研究主要集中在开发治疗运动症状的疗法。非运动症状对针对运动功能缺损的治疗没有反应,因此迫切需要开发能够兼顾运动和非运动功能缺损的新方法。干细胞移植对PD具有潜在的治疗作用,但在这类细胞治疗方案中,疾病的非运动症状一直主要被忽视。目前有多种类型的干细胞可用于移植治疗,包括成体组织(如骨髓、胎盘)来源的间充质干细胞。间充质干细胞能够替代和挽救退化的多巴胺能和非多巴胺能细胞,这表明它们在治疗PD的运动和非运动症状方面具有潜力,本文将对此进行讨论。

相似文献

1
Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells.
Expert Rev Neurother. 2015 Oct;15(10):1231-40. doi: 10.1586/14737175.2015.1091727. Epub 2015 Sep 22.
2
The prospective role of mesenchymal stem cells in Parkinson's disease.
Parkinsonism Relat Disord. 2024 Oct;127:107087. doi: 10.1016/j.parkreldis.2024.107087. Epub 2024 Aug 10.
3
Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease.
Curr Stem Cell Res Ther. 2017;12(4):326-347. doi: 10.2174/1574888X12666161114122059.
4
Stem cell-based therapy for Parkinson's disease with a focus on human endometrium-derived mesenchymal stem cells.
J Cell Physiol. 2019 Feb;234(2):1326-1335. doi: 10.1002/jcp.27182. Epub 2018 Aug 26.
5
Old and new challenges in Parkinson's disease therapeutics.
Prog Neurobiol. 2017 Sep;156:69-89. doi: 10.1016/j.pneurobio.2017.04.006. Epub 2017 Apr 27.
6
Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review.
Neurol Sci. 2020 May;41(5):1051-1061. doi: 10.1007/s10072-020-04240-9. Epub 2020 Jan 9.
7
Mesenchymal stem cells and neuroregeneration in Parkinson's disease.
Exp Neurol. 2013 Sep;247:25-38. doi: 10.1016/j.expneurol.2013.03.016. Epub 2013 Mar 28.
8
Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinson's Disease.
Curr Stem Cell Res Ther. 2019;14(7):549-569. doi: 10.2174/1574888X14666190301150210.

引用本文的文献

1
Coadministration of 6-Shogaol and Levodopa Alleviates Parkinson's Disease-Related Pathology in Mice.
Biomol Ther (Seoul). 2024 Sep 1;32(5):523-530. doi: 10.4062/biomolther.2024.075. Epub 2024 Aug 2.
2
Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence.
Curr Neuropharmacol. 2023;21(3):560-577. doi: 10.2174/1570159X20666221005090126.
4
Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders.
Front Med (Lausanne). 2022 Mar 31;9:813204. doi: 10.3389/fmed.2022.813204. eCollection 2022.
5
Enriched Environment and Exercise Enhance Stem Cell Therapy for Stroke, Parkinson's Disease, and Huntington's Disease.
Front Cell Dev Biol. 2022 Mar 3;10:798826. doi: 10.3389/fcell.2022.798826. eCollection 2022.
9
Non-Motor Symptoms after One Week of High Cadence Cycling in Parkinson's Disease.
Int J Environ Res Public Health. 2019 Jun 14;16(12):2104. doi: 10.3390/ijerph16122104.

本文引用的文献

3
4
Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.
Exp Biol Med (Maywood). 2014 Nov;239(11):1421-32. doi: 10.1177/1535370214538588. Epub 2014 Jun 17.
5
Local control of striatal dopamine release.
Front Behav Neurosci. 2014 May 23;8:188. doi: 10.3389/fnbeh.2014.00188. eCollection 2014.
6
Bridging between transplantation therapy and neurotrophic factors in Parkinson's disease.
Front Biosci (Elite Ed). 2014 Jun 1;6(2):225-35. doi: 10.2741/E704.
7
Mesenchymal stem cell delivery routes and fate.
Int J Stem Cells. 2008 Nov;1(1):1-7. doi: 10.15283/ijsc.2008.1.1.1.
8
Dysautonomia in Parkinson disease.
Compr Physiol. 2014 Apr;4(2):805-26. doi: 10.1002/cphy.c130026.
9
Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation.
Stem Cell Reports. 2014 Mar 6;2(3):337-50. doi: 10.1016/j.stemcr.2014.01.013. eCollection 2014 Mar 11.
10
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Hum Exp Toxicol. 2014 Dec;33(12):1217-31. doi: 10.1177/0960327114524238. Epub 2014 Feb 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验